AR121065A1 - Agente para tratar o prevenir demencia - Google Patents

Agente para tratar o prevenir demencia

Info

Publication number
AR121065A1
AR121065A1 ARP210100097A ARP210100097A AR121065A1 AR 121065 A1 AR121065 A1 AR 121065A1 AR P210100097 A ARP210100097 A AR P210100097A AR P210100097 A ARP210100097 A AR P210100097A AR 121065 A1 AR121065 A1 AR 121065A1
Authority
AR
Argentina
Prior art keywords
dementia
rgma
antibody
treat
agent
Prior art date
Application number
ARP210100097A
Other languages
English (en)
Inventor
Toshihide Yamashita
Takahide Itokazu
Hiroki Uno
Hirokazu Ishida
Original Assignee
Univ Osaka
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Mitsubishi Tanabe Pharma Corp filed Critical Univ Osaka
Publication of AR121065A1 publication Critical patent/AR121065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un agente, caracterizado porque es para tratar o prevenir una demencia seleccionada entre demencia diabética y demencia vascular que comprende una sustancia inhibidora de RGMa. Reivindicación 5: El agente preventivo o terapéutico de acuerdo con la reivindicación 4, caracterizado porque el anticuerpo anti-RGMa neutralizante es un anticuerpo humanizado. Reivindicación 6: El agente preventivo o terapéutico de acuerdo con la reivindicación 4 ó 5, caracterizado porque el anticuerpo anti-RGMa neutralizante es un anticuerpo que reconoce una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 16, 36, 37, 38 y 39. Reivindicación 8: Un método para prevenir o tratar una demencia seleccionada entre demencia diabética y demencia vascular, caracterizado porque comprende administrar una dosis eficaz de una sustancia inhibidora de RGMa a un mamífero que necesita del tratamiento.
ARP210100097A 2020-01-15 2021-01-15 Agente para tratar o prevenir demencia AR121065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020004403 2020-01-15

Publications (1)

Publication Number Publication Date
AR121065A1 true AR121065A1 (es) 2022-04-13

Family

ID=76863789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100097A AR121065A1 (es) 2020-01-15 2021-01-15 Agente para tratar o prevenir demencia

Country Status (13)

Country Link
US (1) US20230090965A1 (es)
EP (1) EP4091633A1 (es)
JP (1) JPWO2021145435A1 (es)
KR (1) KR20220113794A (es)
CN (1) CN114945385A (es)
AR (1) AR121065A1 (es)
AU (1) AU2021207010A1 (es)
BR (1) BR112022013944A2 (es)
CA (1) CA3168209A1 (es)
IL (1) IL294769A (es)
MX (1) MX2022008588A (es)
TW (1) TW202140555A (es)
WO (1) WO2021145435A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001294198C1 (en) 2000-10-06 2019-04-04 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
AU2005221471A1 (en) 2004-03-11 2005-09-22 Bioclues, Inc Axon regeneration promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP6271441B2 (ja) 2012-01-27 2018-01-31 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 神経突起変性に関連する疾患を診断および治療するための組成物および方法
KR102613528B1 (ko) 2015-04-28 2023-12-12 미쓰비시 타나베 파마 코퍼레이션 RGMa 결합 단백질 및 그 사용

Also Published As

Publication number Publication date
US20230090965A1 (en) 2023-03-23
AU2021207010A1 (en) 2022-08-25
KR20220113794A (ko) 2022-08-16
IL294769A (en) 2022-09-01
WO2021145435A1 (ja) 2021-07-22
CA3168209A1 (en) 2021-07-22
MX2022008588A (es) 2022-08-10
TW202140555A (zh) 2021-11-01
CN114945385A (zh) 2022-08-26
BR112022013944A2 (pt) 2022-09-20
JPWO2021145435A1 (es) 2021-07-22
EP4091633A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
Angulo et al. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
Bechara et al. Effectiveness of low-intensity extracorporeal shock wave therapy on patients with erectile dysfunction (ED) who have failed to respond to PDE5i therapy. A pilot study
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
EP4299127A3 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
CL2021002176A1 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040)
CL2022000214A1 (es) Inhibidores de enzimas
MX2023010657A (es) Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas.
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
AR121065A1 (es) Agente para tratar o prevenir demencia
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
Avellino et al. Common urologic diseases in older men and their treatment: how they impact fertility
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
CL2023002769A1 (es) Un tratamiento de heridas biológicas coloreado que proporciona monitoreo del progreso de curación
AR115722A1 (es) Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
MX2020007404A (es) Metodos y terapia de combincion para tratar cancer.
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.